×
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)

NexImmune Stock Forecast, Price & News

$1.59
-0.13 (-7.56%)
(As of 07/5/2022 04:00 PM ET)
Add
Compare
Today's Range
$1.54
$1.76
50-Day Range
$1.61
$3.23
52-Week Range
$1.51
$18.78
Volume
66,358 shs
Average Volume
216,260 shs
Market Capitalization
$36.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.33

NexImmune MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
424.1% Upside
$8.33 Price Target
Short Interest
Bearish
7.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$255,318 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.16) to ($1.51) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.29 out of 5 stars

Medical Sector

204th out of 1,428 stocks

Pharmaceutical Preparations Industry

95th out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive NEXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NexImmune and its competitors with MarketBeat's FREE daily newsletter.

NexImmune logo

About NexImmune (NASDAQ:NEXI) Stock

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

NEXI Stock News Headlines

What Makes NexImmune, Inc. (NEXI) a New Buy Stock
NexImmune: Selling For Under Cash Value
Neximmune GAAP EPS of -$0.68
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NEXI
Fax
N/A
Employees
74
Year Founded
N/A

Company Calendar

Last Earnings
5/12/2022
Today
7/05/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$8.33
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+424.1%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
4 Analysts

Profitability

Net Income
$-50,900,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.67 per share

Miscellaneous

Free Float
18,616,000
Market Cap
$36.32 million
Optionable
Not Optionable
Beta
1.99














NexImmune Frequently Asked Questions

Should I buy or sell NexImmune stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NexImmune in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NexImmune stock.
View analyst ratings for NexImmune
or view top-rated stocks.

What is NexImmune's stock price forecast for 2022?

4 equities research analysts have issued 12-month price targets for NexImmune's shares. Their NEXI stock forecasts range from $5.00 to $13.00. On average, they anticipate NexImmune's share price to reach $8.33 in the next year. This suggests a possible upside of 424.1% from the stock's current price.
View analysts' price targets for NexImmune
or view top-rated stocks among Wall Street analysts.

How has NexImmune's stock price performed in 2022?

NexImmune's stock was trading at $4.61 at the beginning of the year. Since then, NEXI stock has decreased by 65.5% and is now trading at $1.59.
View the best growth stocks for 2022 here
.

When is NexImmune's next earnings date?

NexImmune is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for NexImmune
.

How were NexImmune's earnings last quarter?

NexImmune, Inc. (NASDAQ:NEXI) released its earnings results on Thursday, May, 12th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.05.
View NexImmune's earnings history
.

Who are NexImmune's key executives?

NexImmune's management team includes the following people:
  • Ms. Kristi Jones R.Ph., CEO, Pres & Director (Age 59, Pay $520.87k)
  • Mr. John Trainer M.B.A., Chief Financial Officer (Age 48, Pay $514.67k)
  • Dr. Jerome Bernard Zeldis M.D., Ph.D., Exec. VP of R&D (Age 72, Pay $405.79k)
  • Dr. Robert Douglas Knight M.D., Chief Medical Officer (Age 71, Pay $454.77k)
  • Dr. Mathias Oelke Ph.D., Chief Scientific Officer (Age 54)
  • Dr. Jeffrey S. Weber M.D., Ph.D., Chief Scientific Advisor, Co-Chairman of Scientific Advisory Board and Member of AI & ID SAB
  • Mr. Karen Haslbeck, Head of HR
  • Dr. Daniel P. Bednarik, Sr. VP of Molecular Engineering & Protein Design
  • Mr. Chad Rubin, Sr. VP of Corp. Affairs
  • Dr. Jack A. Ragheb M.D., Ph.D., Sr. VP of Translational Science

When did NexImmune IPO?

(NEXI) raised $75 million in an IPO on Friday, February 12th 2021. The company issued 4,700,000 shares at $15.00-$17.00 per share. Barclays, Cantor, Raymond James and Allen & Co. acted as the underwriters for the IPO.

What is NexImmune's stock symbol?

NexImmune trades on the NASDAQ under the ticker symbol "NEXI."

How do I buy shares of NexImmune?

Shares of NEXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NexImmune's stock price today?

One share of NEXI stock can currently be purchased for approximately $1.59.

How much money does NexImmune make?

NexImmune (NASDAQ:NEXI) has a market capitalization of $36.32 million. The company earns $-50,900,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis.

How many employees does NexImmune have?

NexImmune employs 74 workers across the globe.

How can I contact NexImmune?

NexImmune's mailing address is 9119 GAITHER ROAD, GAITHERSBURG MD, 20877. The official website for NexImmune is www.neximmune.com. The company can be reached via phone at 301-825-9810 or via email at crubin@soleburytrout.com.

This page (NASDAQ:NEXI) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.